Lexicon Pharmaceuticals IncNASDAQ:LXRX
- LAST PRICE1.6900
- TODAY'S CHANGE (%)0.0800 (4.9689%)
- Bid / Lots1.6600/ 1
- Ask / Lots1.6700/ 1
- Open / Previous Close1.6300 / 1.6100
- Day Range
- 52 Week Range
- Volume2,962,697
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LXRX |
|---|---|---|
| 09:32 ET | 21916 | 1.65 |
| 09:34 ET | 17746 | 1.64 |
| 09:36 ET | 1300 | 1.63 |
| 09:38 ET | 23436 | 1.62 |
| 09:39 ET | 8884 | 1.6299 |
| 09:41 ET | 600 | 1.625 |
| 09:43 ET | 7315 | 1.6294 |
| 09:45 ET | 27239 | 1.645 |
| 09:48 ET | 2754 | 1.6406 |
| 09:50 ET | 1791 | 1.644 |
| 09:52 ET | 3300 | 1.64 |
| 09:54 ET | 20061 | 1.63 |
| 09:56 ET | 2139 | 1.635 |
| 09:57 ET | 43699 | 1.635 |
| 09:59 ET | 1590 | 1.635 |
| 10:01 ET | 17813 | 1.65 |
| 10:03 ET | 7780 | 1.6486 |
| 10:06 ET | 2550 | 1.6401 |
| 10:08 ET | 2300 | 1.645 |
| 10:10 ET | 1313 | 1.645 |
| 10:12 ET | 12786 | 1.635 |
| 10:14 ET | 3460 | 1.6301 |
| 10:15 ET | 22201 | 1.645 |
| 10:17 ET | 6299 | 1.645 |
| 10:19 ET | 612 | 1.645 |
| 10:21 ET | 485 | 1.65 |
| 10:24 ET | 14200 | 1.64 |
| 10:26 ET | 10889 | 1.6306 |
| 10:28 ET | 29890 | 1.645 |
| 10:30 ET | 15674 | 1.6399 |
| 10:32 ET | 16059 | 1.645 |
| 10:33 ET | 1017 | 1.645 |
| 10:35 ET | 23546 | 1.645 |
| 10:37 ET | 3042 | 1.645 |
| 10:39 ET | 300 | 1.645 |
| 10:42 ET | 900 | 1.65 |
| 10:44 ET | 1100 | 1.65 |
| 10:46 ET | 300 | 1.645 |
| 10:48 ET | 1365 | 1.65 |
| 10:50 ET | 611 | 1.645 |
| 10:51 ET | 16753 | 1.645 |
| 10:53 ET | 583 | 1.65 |
| 10:55 ET | 1636 | 1.65 |
| 10:57 ET | 961 | 1.645 |
| 11:00 ET | 555 | 1.645 |
| 11:02 ET | 56196 | 1.655 |
| 11:04 ET | 3126 | 1.66 |
| 11:06 ET | 18233 | 1.655 |
| 11:08 ET | 1420 | 1.6594 |
| 11:09 ET | 9381 | 1.655 |
| 11:11 ET | 14260 | 1.655 |
| 11:13 ET | 900 | 1.66 |
| 11:15 ET | 2519 | 1.655 |
| 11:18 ET | 7800 | 1.655 |
| 11:20 ET | 154 | 1.6579 |
| 11:22 ET | 38778 | 1.645 |
| 11:24 ET | 300 | 1.645 |
| 11:26 ET | 11181 | 1.646 |
| 11:27 ET | 13256 | 1.645 |
| 11:29 ET | 612 | 1.645 |
| 11:31 ET | 13800 | 1.645 |
| 11:33 ET | 1000 | 1.64 |
| 11:36 ET | 1400 | 1.645 |
| 11:38 ET | 339 | 1.65 |
| 11:40 ET | 2000 | 1.646 |
| 11:42 ET | 700 | 1.645 |
| 11:45 ET | 800 | 1.645 |
| 11:47 ET | 100 | 1.6497 |
| 11:49 ET | 57420 | 1.655 |
| 11:51 ET | 2044 | 1.655 |
| 11:54 ET | 32950 | 1.655 |
| 11:56 ET | 100 | 1.655 |
| 11:58 ET | 400 | 1.66 |
| 12:00 ET | 2205 | 1.655 |
| 12:02 ET | 900 | 1.655 |
| 12:03 ET | 138475 | 1.665 |
| 12:05 ET | 1725 | 1.665 |
| 12:07 ET | 3688 | 1.67 |
| 12:09 ET | 1819 | 1.67 |
| 12:12 ET | 45701 | 1.67 |
| 12:14 ET | 1047 | 1.6651 |
| 12:16 ET | 600 | 1.67 |
| 12:18 ET | 11000 | 1.6616 |
| 12:20 ET | 5501 | 1.67 |
| 12:21 ET | 397 | 1.6619 |
| 12:23 ET | 892 | 1.665 |
| 12:25 ET | 2754 | 1.66 |
| 12:27 ET | 11885 | 1.665 |
| 12:32 ET | 600 | 1.665 |
| 12:34 ET | 1500 | 1.6606 |
| 12:36 ET | 600 | 1.665 |
| 12:38 ET | 1100 | 1.665 |
| 12:39 ET | 30223 | 1.665 |
| 12:41 ET | 50905 | 1.6719 |
| 12:43 ET | 5300 | 1.675 |
| 12:45 ET | 1117 | 1.6799 |
| 12:48 ET | 1600 | 1.675 |
| 12:50 ET | 1600 | 1.675 |
| 12:52 ET | 200 | 1.6706 |
| 12:54 ET | 7256 | 1.6719 |
| 12:56 ET | 1300 | 1.675 |
| 12:57 ET | 700 | 1.675 |
| 01:01 ET | 907 | 1.67 |
| 01:03 ET | 1100 | 1.675 |
| 01:06 ET | 23600 | 1.6701 |
| 01:08 ET | 100 | 1.675 |
| 01:12 ET | 1700 | 1.67 |
| 01:14 ET | 300 | 1.675 |
| 01:15 ET | 1216 | 1.675 |
| 01:17 ET | 400 | 1.675 |
| 01:19 ET | 893 | 1.6706 |
| 01:21 ET | 700 | 1.6706 |
| 01:24 ET | 300 | 1.68 |
| 01:26 ET | 1154 | 1.6706 |
| 01:28 ET | 700 | 1.675 |
| 01:30 ET | 98769 | 1.685 |
| 01:32 ET | 16953 | 1.685 |
| 01:33 ET | 7540 | 1.69 |
| 01:35 ET | 14669 | 1.685 |
| 01:37 ET | 4705 | 1.685 |
| 01:39 ET | 2800 | 1.685 |
| 01:42 ET | 1400 | 1.685 |
| 01:44 ET | 100 | 1.6833 |
| 01:48 ET | 4000 | 1.685 |
| 01:50 ET | 51100 | 1.685 |
| 01:51 ET | 2226 | 1.685 |
| 01:53 ET | 126498 | 1.67 |
| 01:55 ET | 12640 | 1.67 |
| 01:57 ET | 8793 | 1.675 |
| 02:00 ET | 20600 | 1.675 |
| 02:02 ET | 6372 | 1.672 |
| 02:04 ET | 46214 | 1.66 |
| 02:06 ET | 110983 | 1.655 |
| 02:08 ET | 100 | 1.655 |
| 02:09 ET | 30899 | 1.67 |
| 02:13 ET | 916 | 1.665 |
| 02:15 ET | 900 | 1.67 |
| 02:18 ET | 800 | 1.67 |
| 02:22 ET | 8502 | 1.665 |
| 02:24 ET | 300 | 1.665 |
| 02:26 ET | 604 | 1.665 |
| 02:27 ET | 10590 | 1.675 |
| 02:29 ET | 100 | 1.675 |
| 02:31 ET | 5359 | 1.6726 |
| 02:33 ET | 3150 | 1.675 |
| 02:36 ET | 664 | 1.675 |
| 02:38 ET | 1100 | 1.675 |
| 02:40 ET | 300 | 1.675 |
| 02:44 ET | 1496 | 1.675 |
| 02:45 ET | 100 | 1.675 |
| 02:47 ET | 800 | 1.675 |
| 02:49 ET | 701 | 1.6799 |
| 02:51 ET | 4852 | 1.68 |
| 02:54 ET | 3185 | 1.675 |
| 02:56 ET | 1980 | 1.67 |
| 02:58 ET | 200 | 1.675 |
| 03:00 ET | 4198 | 1.675 |
| 03:02 ET | 9700 | 1.675 |
| 03:03 ET | 205627 | 1.69 |
| 03:05 ET | 43908 | 1.69 |
| 03:07 ET | 70015 | 1.7 |
| 03:09 ET | 7190 | 1.69 |
| 03:12 ET | 28846 | 1.695 |
| 03:14 ET | 21360 | 1.695 |
| 03:16 ET | 13322 | 1.695 |
| 03:18 ET | 600 | 1.695 |
| 03:20 ET | 1410 | 1.695 |
| 03:21 ET | 7904 | 1.695 |
| 03:23 ET | 856 | 1.695 |
| 03:25 ET | 14680 | 1.691 |
| 03:27 ET | 23305 | 1.6997 |
| 03:30 ET | 33936 | 1.6906 |
| 03:32 ET | 1800 | 1.695 |
| 03:34 ET | 1634 | 1.695 |
| 03:36 ET | 7973 | 1.695 |
| 03:38 ET | 21738 | 1.695 |
| 03:39 ET | 31373 | 1.695 |
| 03:41 ET | 101035 | 1.705 |
| 03:43 ET | 143435 | 1.695 |
| 03:45 ET | 1438 | 1.6906 |
| 03:48 ET | 96097 | 1.685 |
| 03:50 ET | 21323 | 1.685 |
| 03:52 ET | 2543 | 1.685 |
| 03:54 ET | 15886 | 1.685 |
| 03:56 ET | 26609 | 1.685 |
| 03:57 ET | 40032 | 1.685 |
| 03:59 ET | 199528 | 1.69 |
Oct 3, 2024
DJ Lexicon Pharma Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 7:23AM ET on Thursday Oct 03, 2024 by Dow Jones
7:23AM ET on Thursday Oct 03, 2024 by Dow Jones
Sep 27, 2024
DJ Lexicon Pharma Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 11:32AM ET on Friday Sep 27, 2024 by Dow Jones
11:32AM ET on Friday Sep 27, 2024 by Dow JonesLexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress, from 8:00AM ET on Friday Sep 27, 2024 by Dow Jones
8:00AM ET on Friday Sep 27, 2024 by Dow Jones
Sep 16, 2024
DJ Lexicon Pharma President, Oper Chief Jeffery Wade Leaving, from 8:29AM ET on Monday Sep 16, 2024 by Dow Jones
8:29AM ET on Monday Sep 16, 2024 by Dow JonesPress Release: Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer, from 8:00AM ET on Monday Sep 16, 2024 by Dow Jones
8:00AM ET on Monday Sep 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Lexicon Pharmaceuticals Inc | 610.9M | -2.2x | --- |
Scholar Rock Holding Corp | 593.8M | -3.3x | --- |
Savara Inc | 628.8M | -8.8x | --- |
Neurogene Inc | 631.4M | -9.9x | --- |
Humacyte Inc | 649.3M | -4.3x | --- |
Oculis Holding AG | 551.0M | -6.4x | --- |
Company Information
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Contact Information
- Headquarters
- 2445 Technology Forest Blvd, 11Th FloorTHE WOODLANDS, TX, United States 77381
- Phone
- 281-863-3000
- Fax
- 281-863-8088
Executives
- Independent Chairman of the Board
- Raymond Debbane
- President, Chief Operating Officer
- Jeffrey Wade
- Chief Executive Officer, Director
- Michael Exton
- Executive Vice President - Innovation and Chemical Sciences
- Alan Main
- Senior Vice President, General Counsel
- Brian Crum
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $610.9M |
|---|---|
Revenue (TTM) | $3.6M |
Shares Outstanding | 361.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.27 |
EPS | $-0.78 |
Book Value | $0.38 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | 167.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5,412.11% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
